promising cancer treatment targets rare flaw
Sunday 20 July 2025
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle

At a major cancer conference

Promising Cancer Treatment Targets Rare Flaw

Themuslimchronicle, themuslimchronicle

Themuslimchronicle, themuslimchroniclePromising Cancer Treatment Targets Rare Flaw

An experimental cancer medicine
New York - Muslimchronicle

An experimental cancer medicine called larotrectinib has shown promise treating a diverse range of cancers in people young and old, researchers said at a major cancer conference in the United States.

The treatment targets a genetic abnormality which is often found in rare cancers -- including salivary gland cancer, juvenile breast cancer, and a soft tissue cancer known as infantile fibrosarcoma -- which are particularly difficult to treat.

This abnormality also occurs in about 0.5 percent to one percent of many common cancers.

In the study released at the American Society of Clinical Oncology conference, 76 percent of cancer patients -- both children and adults with 17 different kinds of cancer -- responded well to the medicine.

A total of 79 percent were alive after one year. The study is ongoing.

Twelve percent went into complete remission from their cancer.

The clinical trial included 55 patients -- 43 adults and 12 children. All had advanced cancers in various organs, including the colon, pancreas and lung, as well as melanoma.

"These findings embody the original promise of precision oncology: treating a patient based on the type of mutation, regardless of where the cancer originated," said lead study author David Hyman, chief of early drug development at Memorial Sloan Kettering Cancer Center in New York. 

"We believe that the dramatic response of tumors with TRK fusions to larotrectinib supports widespread genetic testing in patients with advanced cancer to see if they have this abnormality."

Made by Loxo Oncology Inc., larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) fusion proteins.

TRK proteins are a product of a genetic abnormality when a TRK gene in a cancer cell fuses with one of many other genes, researchers said.

The U.S. Food and Drug Administration has not yet approved the treatment for widespread use.

The treatment was well tolerated by patients, and the most common side effects were fatigue and mild dizziness.

"If approved, larotrectinib could become the first therapy of any kind to be developed and approved simultaneously in adults and children, and the first targeted therapy to be indicated for a molecular definition of cancer that spans all traditionally-defined types of tumors," said Hyman.

Source: AFP

themuslimchronicle
themuslimchronicle

GMT 07:55 2017 Tuesday ,26 December

Florida orange industry hit

GMT 08:18 2017 Monday ,18 December

Judge Temporarily Blocks New rules

GMT 00:27 2017 Saturday ,02 December

Serious health risks waste burning

GMT 12:13 2017 Tuesday ,17 October

Mass Cholera Vaccinations Begin

GMT 07:54 2017 Saturday ,19 August

UN demands civilian access
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

promising cancer treatment targets rare flaw promising cancer treatment targets rare flaw

 



Themuslimchronicle, themuslimchronicle

GMT 22:10 2017 Friday ,31 March

April 20 - May 20

GMT 09:58 2017 Saturday ,19 August

All Black star Kaino returns home to deal

GMT 06:35 2015 Tuesday ,13 January

Ronaldo wins 2014 Ballon d'Or

GMT 13:37 2012 Monday ,20 February

Lamborghini Diablo

GMT 00:52 2013 Sunday ,22 December

PS4 Xbox 1 power consumption analysis points to Sony

GMT 09:44 2016 Monday ,26 September

Fuel tanker fire extinguished in Gulf of Mexico

GMT 10:43 2011 Wednesday ,23 November

2012 Acura TL SH-AWD

GMT 04:58 2014 Friday ,15 August

'Flashmob' robots swarm themselves into shape

GMT 04:29 2012 Sunday ,14 October

Classical poetry of the Shafi\'i

GMT 13:18 2016 Tuesday ,06 December

Teachers around the world share their stories

GMT 09:59 2017 Wednesday ,22 February

Hope for Dubai oil workers who are owed pay

GMT 14:10 2017 Friday ,03 February

Reasons of growth rate conflicting numbers

GMT 09:32 2017 Sunday ,29 October

Hiroshima survivor to accept Nobel Prize

GMT 23:09 2017 Wednesday ,15 February

Indian PSLV rocket lifts off with record 104 satellites

GMT 14:23 2016 Friday ,01 January

Japanese hurler Maeda reportedly headed to Dodgers

GMT 14:28 2016 Wednesday ,27 January

Sony moves PlayStation business to Silicon Valley

GMT 13:19 2017 Wednesday ,29 March

Belstaff appoints Karla Otto

GMT 13:44 2017 Friday ,24 March

Arab Spring: Where are the leaders now?
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
 
 Themuslimchronicle Facebook,themuslimchronicle facebook  Themuslimchronicle Twitter,themuslimchronicle twitter Themuslimchronicle Rss,themuslimchronicle rss  Themuslimchronicle Youtube,themuslimchronicle youtube  Themuslimchronicle Youtube,themuslimchronicle youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

muslimchronicle muslimchronicle muslimchronicle muslimchronicle
themuslimchronicle themuslimchronicle themuslimchronicle
themuslimchronicle
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
themuslimchronicle, themuslimchronicle, themuslimchronicle